PMC:7074432 / 1704-1994 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"66","span":{"begin":39,"end":48},"obj":"Species"},{"id":"81","span":{"begin":51,"end":64},"obj":"Gene"},{"id":"96","span":{"begin":76,"end":89},"obj":"Gene"},{"id":"97","span":{"begin":173,"end":181},"obj":"Species"},{"id":"98","span":{"begin":230,"end":238},"obj":"Species"},{"id":"99","span":{"begin":272,"end":280},"obj":"Species"},{"id":"104","span":{"begin":136,"end":145},"obj":"Species"},{"id":"105","span":{"begin":248,"end":259},"obj":"Chemical"}],"attributes":[{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"Tax:2697049"},{"id":"A81","pred":"tao:has_database_id","subj":"81","obj":"Gene:4758"},{"id":"A96","pred":"tao:has_database_id","subj":"96","obj":"Gene:4758"},{"id":"A97","pred":"tao:has_database_id","subj":"97","obj":"Tax:1335626"},{"id":"A98","pred":"tao:has_database_id","subj":"98","obj":"Tax:9606"},{"id":"A99","pred":"tao:has_database_id","subj":"99","obj":"Tax:9606"},{"id":"A104","pred":"tao:has_database_id","subj":"104","obj":"Tax:11309"},{"id":"A105","pred":"tao:has_database_id","subj":"105","obj":"MESH:D053139"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ut these are not evaluated till now in 2019-nCoV.\n\nNeuraminidase inhibitors\nNeuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive "}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T108","span":{"begin":65,"end":75},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T107","span":{"begin":90,"end":100},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T106","span":{"begin":173,"end":181},"obj":"SP_9"},{"id":"T105","span":{"begin":248,"end":259},"obj":"CHEBI:7798;CHEBI:7798"},{"id":"T63","span":{"begin":39,"end":48},"obj":"SP_7"}],"text":"ut these are not evaluated till now in 2019-nCoV.\n\nNeuraminidase inhibitors\nNeuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive "}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T13","span":{"begin":136,"end":145},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"}],"text":"ut these are not evaluated till now in 2019-nCoV.\n\nNeuraminidase inhibitors\nNeuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T8","span":{"begin":153,"end":154},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T9","span":{"begin":216,"end":217},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T10","span":{"begin":227,"end":229},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"}],"text":"ut these are not evaluated till now in 2019-nCoV.\n\nNeuraminidase inhibitors\nNeuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T14","span":{"begin":51,"end":75},"obj":"Chemical"},{"id":"T15","span":{"begin":65,"end":75},"obj":"Chemical"},{"id":"T16","span":{"begin":76,"end":100},"obj":"Chemical"},{"id":"T17","span":{"begin":90,"end":100},"obj":"Chemical"},{"id":"T18","span":{"begin":248,"end":259},"obj":"Chemical"}],"attributes":[{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_52425"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_52425"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"}],"text":"ut these are not evaluated till now in 2019-nCoV.\n\nNeuraminidase inhibitors\nNeuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive "}

{"project":"LitCovid-sentences","denotations":[{"id":"T14","span":{"begin":51,"end":75},"obj":"Sentence"},{"id":"T15","span":{"begin":76,"end":268},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ut these are not evaluated till now in 2019-nCoV.\n\nNeuraminidase inhibitors\nNeuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive "}